Ingredient or product comparison
AHK-Cu vs Minoxidil: Side Effects and Tolerability Comparison
Contact dermatitis incidence 15–25% (primarily from propylene glycol vehicle, not minoxidil itself) <5% (peptides rarely trigger immune response) AHK-Cu shows better skin tolerability in sensitive patients Scalp dryness/flaking Common. Occurs in 30–40% of user
This source-based comparison does not add ratings or recommend a winner.
- Contact dermatitis incidence
- 15–25% (primarily from propylene glycol vehicle, not minoxidil itself)
- <5% (peptides rarely trigger immune response)
- AHK-Cu shows better skin tolerability in sensitive patients
- Scalp dryness/flaking
- Common. Occurs in 30–40% of users
- Rare. Peptide serums often include hydrating carriers
- Minoxidil formulations worsen seborrheic dermatitis; AHK-Cu does not
- Systemic absorption risk
- Minimal with topical use, but oral minoxidil (off-label for hair loss) carries cardiovascular risk
- Negligible. Peptides do not cross dermal barrier in meaningful amounts
- Topical minoxidil is safe for most; oral minoxidil requires prescriber oversight
- Initial shedding phase
- 2–4 weeks after starting. Telogen hairs shed as follicles shift to anagen
- Rare. Shedding not consistently reported in trials
- Minoxidil shedding alarms patients but indicates efficacy; AHK-Cu avoids this
- Application frequency
- Twice daily (morning + evening) for sustained effect
- Once daily (evening preferred for overnight absorption)
- Compliance strongly favours AHK-Cu's simpler regimen
- Minoxidil's twice-daily requirement is the single biggest compliance barrier. Patients who skip even one dose per day see measurably lower regrowth rates. AHK-Cu's once-nightly application removes that friction, which matters over 12+ month treatment timelines.